Healthcare · Biotechnology
SGMO faces extreme distress with a -310.81% profit margin and a devastating -95.01% revenue surprise, signaling severe operational viability risks for investors.
AI-generated summary — powered by BigEarnings.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-14 | Q1 2026 | -0.06 | -0.08 | -33.33% | $1.4M | ❌ Miss | +0.00% | +0.00% | +0.00% |
| 2026-03-30 | Q4 2025 | -0.02 | -0.11 | -450.00% | $14.2M | ❌ Miss | -19.66% | -16.66% | -56.78% |
| 2025-11-06 |
| Q3 2025 |
| -0.07 |
| -0.11 |
| -57.14% |
| $581,000 |
| ❌ Miss |
| -16.29% |
| -14.56% |
| -9.85% |
| 2025-08-07 | Q2 2025 | -0.10 | -0.08 | +20.00% | $18.3M | ✅ Beat | -5.33% | +11.89% | +8.79% |
| 2025-03-17 | Q4 2024 | -0.09 | -0.11 | -22.22% | $7.6M | ❌ Miss | -16.23% | -13.86% | -26.91% |
| 2024-11-12 | Q3 2024 | -0.03 | 0.04 | +233.33% | $49.4M | ✅ Beat | -9.96% | -27.68% | -29.52% |
| 2024-08-06 | Q2 2024 | -0.15 | -0.18 | -20.00% | $356,000 | ❌ Miss | -13.46% | -1.52% | -24.13% |
| 2024-03-13 | Q4 2023 | -0.26 | -0.34 | -30.77% | $2.0M | ❌ Miss | -8.83% | -10.58% | -36.69% |
Showing last 8 quarters.